The plant located at Verna has had an inspection by UK Medicines and Healthcare products Regulatory Agency (MHRA) from February 14-17, Marksans Pharma said in a filing to BSE.
"The same has been completed without any critical observations," it added.
The company, which makes formulations at the facility, is awaiting further instruction from the agency in this regard, Marksans Pharma said.
Marksans Pharma stock was trading at sharply up by 19.46 per cent at Rs 48.50 per on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content